[go: up one dir, main page]

WO2009004822A1 - 抗Muc17抗体 - Google Patents

抗Muc17抗体 Download PDF

Info

Publication number
WO2009004822A1
WO2009004822A1 PCT/JP2008/001777 JP2008001777W WO2009004822A1 WO 2009004822 A1 WO2009004822 A1 WO 2009004822A1 JP 2008001777 W JP2008001777 W JP 2008001777W WO 2009004822 A1 WO2009004822 A1 WO 2009004822A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
muc17
seq
bind
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001777
Other languages
English (en)
French (fr)
Inventor
Kiyotaka Nakano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forerunner Pharma Research Co Ltd
Original Assignee
Forerunner Pharma Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Research Co Ltd filed Critical Forerunner Pharma Research Co Ltd
Priority to AU2008272330A priority Critical patent/AU2008272330A1/en
Priority to EP08790149A priority patent/EP2172483A4/en
Priority to CN200880023060A priority patent/CN101687924A/zh
Priority to CA002691734A priority patent/CA2691734A1/en
Priority to US12/667,595 priority patent/US8546546B2/en
Priority to JP2009521537A priority patent/JP5938816B2/ja
Publication of WO2009004822A1 publication Critical patent/WO2009004822A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G01N33/5753—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　Mucin　17（Muc17）に結合する抗体が開示される。好ましくは、本発明の抗体は、配列番号３のペプチドに結合し、かつ配列番号４のペプチドおよび配列番号５のペプチドには結合しない。本発明の抗体を含む抗癌剤、好ましくは膵臓癌に対する抗癌剤、ならびに本発明の抗体、好ましくは、分泌型Muc17に結合しない抗体を用いることを特徴とする癌の診断方法も開示される。
PCT/JP2008/001777 2007-07-04 2008-07-03 抗Muc17抗体 Ceased WO2009004822A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2008272330A AU2008272330A1 (en) 2007-07-04 2008-07-03 Anti-Muc17 antibody
EP08790149A EP2172483A4 (en) 2007-07-04 2008-07-03 ANTI-MUC17 ANTIBODY
CN200880023060A CN101687924A (zh) 2007-07-04 2008-07-03 抗Muc17抗体
CA002691734A CA2691734A1 (en) 2007-07-04 2008-07-03 Anti-muc17 antibody
US12/667,595 US8546546B2 (en) 2007-07-04 2008-07-03 Anti-Muc 17 antibody
JP2009521537A JP5938816B2 (ja) 2007-07-04 2008-07-03 抗Ｍｕｃ１７抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-176319 2007-07-04
JP2007176319 2007-07-04

Publications (1)

Publication Number Publication Date
WO2009004822A1 true WO2009004822A1 (ja) 2009-01-08

Family

ID=40225887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001777 Ceased WO2009004822A1 (ja) 2007-07-04 2008-07-03 抗Muc17抗体

Country Status (7)

Country Link
US (1) US8546546B2 (ja)
EP (1) EP2172483A4 (ja)
JP (1) JP5938816B2 (ja)
CN (1) CN101687924A (ja)
AU (1) AU2008272330A1 (ja)
CA (1) CA2691734A1 (ja)
WO (1) WO2009004822A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119691A1 (ja) * 2009-04-16 2010-10-21 国立大学法人東京大学 抗tmprss11e抗体を用いた癌の診断と治療
JP2021508465A (ja) * 2017-12-29 2021-03-11 アムジェン インコーポレイテッド Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
WO2023066336A1 (zh) * 2021-10-21 2023-04-27 江苏先声药业有限公司 抗muc17纳米抗体及其应用
JP2023518225A (ja) * 2020-03-19 2023-04-28 アムジエン・インコーポレーテツド ムチン１７に対する抗体及びその使用
KR102910479B1 (ko) 2017-12-29 2026-01-09 암젠 인크 Muc17 및 cd3에 대한 이중특이적 항체 구축물

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119869B2 (en) * 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
CA2871116A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP3489261B1 (en) 2012-08-24 2020-10-21 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US9907593B2 (en) 2014-08-05 2018-03-06 Woven Orthopedic Technologies, Llc Woven retention devices, systems and methods
US20180221059A1 (en) 2015-08-05 2018-08-09 Woven Orthopedic Technologies, Llc Tapping devices, systems and methods for use in bone tissue
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
EP3988111A1 (en) 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
JP7137563B2 (ja) 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体
US11395681B2 (en) 2016-12-09 2022-07-26 Woven Orthopedic Technologies, Llc Retention devices, lattices and related systems and methods
AU2019208025A1 (en) 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
CN120603853A (zh) * 2023-02-03 2025-09-05 山东先声生物制药有限公司 针对muc17和cd3的双特异性抗体及其应用
CN118667026A (zh) * 2023-03-15 2024-09-20 三生国健药业（上海）股份有限公司 抗muc17*cd3*cd28三特异性抗体
CN117534750B (zh) * 2023-10-16 2024-06-11 遵义医科大学珠海校区 一种抗新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用
CN120554518A (zh) * 2024-02-28 2025-08-29 杭州中美华东制药有限公司 抗Mucin 17抗体、其偶联物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061739A1 (fr) * 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20050100925A1 (en) * 2003-11-10 2005-05-12 Surinder Batra MUC17 encoding nucleic acid sequences, polypeptides, antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061739A1 (fr) * 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20050100925A1 (en) * 2003-11-10 2005-05-12 Surinder Batra MUC17 encoding nucleic acid sequences, polypeptides, antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS Database accession no. 2003:421452 *
HO JENNY J L ET AL.: "N-glycosylation is required for the surface localization of MUC17 mucin", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 23, no. 3, 2003, pages 585 - 592, XP009134842 *
J R GUM ET AL.: "MUC17, a Novel membrane- tethered mucin", BIOCHEM BIOPHYS RES COMMUN, vol. 291, 2002, pages 466 - 475, XP002443029 *
N MONIAUX ET AL.: "Characterizatopn of Human Mucin MUC17", J BIOL CHEM, vol. 281, no. 33, 2006, pages 23676 - 23685, XP008129451 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119691A1 (ja) * 2009-04-16 2010-10-21 国立大学法人東京大学 抗tmprss11e抗体を用いた癌の診断と治療
JP5746018B2 (ja) * 2009-04-16 2015-07-08 国立大学法人 東京大学 抗ｔｍｐｒｓｓ１１ｅ抗体を用いた癌の診断と治療
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
JP2021508465A (ja) * 2017-12-29 2021-03-11 アムジェン インコーポレイテッド Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
JP2023134497A (ja) * 2017-12-29 2023-09-27 アムジェン インコーポレイテッド Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
JP7605913B2 (ja) 2017-12-29 2024-12-24 アムジェン インコーポレイテッド Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
KR102910479B1 (ko) 2017-12-29 2026-01-09 암젠 인크 Muc17 및 cd3에 대한 이중특이적 항체 구축물
JP2023518225A (ja) * 2020-03-19 2023-04-28 アムジエン・インコーポレーテツド ムチン１７に対する抗体及びその使用
JP7750852B2 (ja) 2020-03-19 2025-10-07 アムジエン・インコーポレーテツド ムチン１７に対する抗体及びその使用
WO2023066336A1 (zh) * 2021-10-21 2023-04-27 江苏先声药业有限公司 抗muc17纳米抗体及其应用

Also Published As

Publication number Publication date
CN101687924A (zh) 2010-03-31
US20100240872A1 (en) 2010-09-23
JP5938816B2 (ja) 2016-06-22
EP2172483A4 (en) 2010-08-04
AU2008272330A1 (en) 2009-01-08
US8546546B2 (en) 2013-10-01
CA2691734A1 (en) 2009-01-08
JPWO2009004822A1 (ja) 2010-08-26
EP2172483A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
WO2009004822A1 (ja) 抗Muc17抗体
NZ597692A (en) Anti-IGF antibodies
WO2008076379A8 (en) Human antibodies to human delta like ligand 4
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2006121422A3 (en) Antibodies against clostridium difficile toxins and uses thereof
GR1006896B (el) Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CA2691692C (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
EP2316847A3 (en) Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2009022157A3 (en) Peptide with improved solubility
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2007094005A3 (en) Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
WO2008013954A3 (en) Tyrosine phosphorylation sites
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2010136483A3 (en) Antigen-binding proteins
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2011098999A3 (en) Chemical preparation of ubiquitin thioesters and modifications thereof
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
WO2008013934A3 (en) Tyrosine phosphorylation sites

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880023060.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790149

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009521537

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2691734

Country of ref document: CA

Ref document number: 2008272330

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008790149

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008272330

Country of ref document: AU

Date of ref document: 20080703

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 543/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12667595

Country of ref document: US